246 related articles for article (PubMed ID: 36755058)
21. CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons.
Abe P; Mueller W; Schütz D; MacKay F; Thelen M; Zhang P; Stumm R
Development; 2014 May; 141(9):1857-63. PubMed ID: 24718993
[TBL] [Abstract][Full Text] [Related]
22. Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
Oishi S; Kuroyanagi T; Kubo T; Montpas N; Yoshikawa Y; Misu R; Kobayashi Y; Ohno H; Heveker N; Furuya T; Fujii N
J Med Chem; 2015 Jul; 58(13):5218-25. PubMed ID: 26042340
[TBL] [Abstract][Full Text] [Related]
23. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
24. Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Bayrak A; Mohr F; Kolb K; Szpakowska M; Shevchenko E; Dicenta V; Rohlfing AK; Kudolo M; Pantsar T; Günther M; Kaczor AA; Poso A; Chevigné A; Pillaiyar T; Gawaz M; Laufer SA
J Med Chem; 2022 Oct; 65(19):13365-13384. PubMed ID: 36150079
[TBL] [Abstract][Full Text] [Related]
25. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
26. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.
Szpakowska M; Nevins AM; Meyrath M; Rhainds D; D'huys T; Guité-Vinet F; Dupuis N; Gauthier PA; Counson M; Kleist A; St-Onge G; Hanson J; Schols D; Volkman BF; Heveker N; Chevigné A
Br J Pharmacol; 2018 May; 175(9):1419-1438. PubMed ID: 29272550
[TBL] [Abstract][Full Text] [Related]
27. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
28. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach.
Costantini S; Raucci R; De Vero T; Castello G; Colonna G
Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308
[TBL] [Abstract][Full Text] [Related]
29. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
31. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
Singh AK; Arya RK; Trivedi AK; Sanyal S; Baral R; Dormond O; Briscoe DM; Datta D
Cytokine Growth Factor Rev; 2013 Feb; 24(1):41-9. PubMed ID: 22989616
[TBL] [Abstract][Full Text] [Related]
32. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
Zieger-Naumann K; Kuhl F; Engele J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
34. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
35. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets.
Puchert M; Engele J
Cell Tissue Res; 2014 Feb; 355(2):239-53. PubMed ID: 24292718
[TBL] [Abstract][Full Text] [Related]
36. Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease.
Werner L; Guzner-Gur H; Dotan I
Theranostics; 2013; 3(1):40-6. PubMed ID: 23382785
[TBL] [Abstract][Full Text] [Related]
37. AMD3100 is a CXCR7 ligand with allosteric agonist properties.
Kalatskaya I; Berchiche YA; Gravel S; Limberg BJ; Rosenbaum JS; Heveker N
Mol Pharmacol; 2009 May; 75(5):1240-7. PubMed ID: 19255243
[TBL] [Abstract][Full Text] [Related]
38. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4.
Uto-Konomi A; McKibben B; Wirtz J; Sato Y; Takano A; Nanki T; Suzuki S
Biochem Biophys Res Commun; 2013 Feb; 431(4):772-6. PubMed ID: 23333329
[TBL] [Abstract][Full Text] [Related]
39. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S
Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762
[TBL] [Abstract][Full Text] [Related]
40. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]